Skip to main content

Table 1 Inhibition rates (% of control) of sorafenib and 5-fluorouracil (5-FU), alone or in combination, in hepatocellular carcinoma (HCC) cells

From: Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma

Cell line

S

F

(S + F)/ p-value(vs. F)

S + F/ p-value(vs. F)

F + S/ p-value(vs. F)

MHCC97H

18.63 ± 3.82

33.30 ± 5.67

29.87 ± 8.83/p = 0.328

22.98 ± 5.93/p = 0.023

42.57 ± 3.29/p = 0.017

SMMC-7721

20.60 ± 3.83

29.65 ± 4.74

30.35 ± 4.86/p = 0.781

23.23 ± 4.43/p = 0.016

53.50 ± 1.97/p = 0.000

  1. S: sorafenib, F: 5-FU.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us